Cagrilintide vs SS-31 (Elamipretide)
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
CagrilintideAnti-Aging & Longevity
SS-31 (Elamipretide)- Summary
- Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
- SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
- Half-Life
- ~7–10 days
- ~2–5 hours
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
- 5–10 mg
- Frequency
- Once weekly
- Daily to several times per week
- Key Benefits
- ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
- Synergistic appetite suppression complementing GLP-1 receptor agonists
- Reduces post-meal glucagon excursions improving glycemic control
- Slows gastric emptying contributing to prolonged satiety
- Once-weekly dosing via subcutaneous injection
- Potential for greater weight loss than semaglutide monotherapy
- Restores mitochondrial function and ATP production
- Protects inner mitochondrial membrane cardiolipin
- Reduces mitochondrial reactive oxygen species (ROS)
- Improves exercise capacity and reduces fatigue
- Cardioprotective — studied in heart failure trials
- Renoprotective — reduces ischemic kidney injury
- Anti-aging via mitochondrial preservation
- Potential in neurodegenerative disease prevention
- Side Effects
- Nausea (most common, especially during titration)
- Vomiting
- Decreased appetite
- Diarrhea
- +2 more
- Injection site irritation
- Nausea (rare)
- Generally well-tolerated in clinical trials
- Stacks With
- —
- —